A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that gave up its Nasdaq spot in a reverse merger with Korro Bio last year.
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially...
Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
Frequency Therapeutics on Monday said an experimental drug it’s developing for a form of hearing loss failed to meet its goal in a mid-stage study. As a result, the company is stopping work on the program and on another hearing loss drug candidate that began clinical testing in December.
Frequency Therapeutics has dosed the first subject in the Phase Ib clinical trial of its hearing restoration candidate, FX-345, to treat sensorineural hearing loss (SNHL).
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results